儿童SARS-CoV-2时间相关多系统炎症综合征(PIMS-TS):德国单中心对瑞士与英国共识声明的真实世界评估
该研究在德国卡塞尔儿童医院回顾性分析了2021年2月至11月治疗的11例PIMS-TS患儿(女:男=2.1:1),按基于瑞士与英国共识声明的本地标准化操作流程治疗。按共识分型:36%为无并发症的高炎症,36%为川崎病样,27%为休克样。休克样患儿在儿科ICU需要循环复苏,所有患儿均接受标准化治疗,中位7.4天后出院回家。作者结论认为瑞士与英国共识声明在真实临床中很有价值,便于早期分型和启动特异性治疗,可能改善结局,但还需随机试验。
要点
- 11例PIMS-TS患儿按瑞士与英国共识分型:36%无并发症高炎症、36%川崎病样、27%休克样。
- 休克样患儿BNP中位954(668-1491)ng/l,高于川崎病样213(173-934)ng/l和无并发症高炎症80(5-257)ng/l,p=0.02。
- 川崎病样患儿肌钙蛋白中位34.7(27.5-58.4)ng/l,高于休克样19.1(14.1-23.4)ng/l和无并发症高炎症1.9(1.9-16.4)ng/l,p=0.02。
- 休克样患儿需要在儿科ICU进行循环复苏;所有患儿均接受基于标准化操作流程的治疗,中位7.4天后出院回家。
- 4-15岁儿童本地估计PIMS-TS发病率为0.92/1000例COVID-19病例。
适用人群与场景
- 2021年2月至11月在德国卡塞尔儿童医院治疗的PIMS-TS患儿,共11例(女:男=2.1:1)。
诊断标准与关键阈值
- 采用瑞士与英国共识声明的分类:无并发症高炎症、川崎病样、休克样疾病。
处置流程与药物剂量
- 患者按基于瑞士与英国共识声明的本地PIMS-TS标准化操作流程治疗。
- 休克样表现的患者在儿科ICU需要循环复苏。
红旗征与不能漏的情况
- 休克样表现:需要在儿科ICU进行循环复苏。
研究设计与关键结果
- 回顾性分析11例PIMS-TS患儿,按瑞士与英国共识分型:36%无并发症高炎症,36%川崎病样,27%休克样。
- 4-15岁儿童本地估计发病率为0.92/1000例COVID-19病例。
- BNP在休克样最高,其次川崎病样,无并发症高炎症最低:中位954(668-1491)vs 213(173-934)vs 80(5-257)ng/l,p=0.02。
- 肌钙蛋白在川崎病样最高,其次休克样,无并发症高炎症最低:中位34.7(27.5-58.4)vs 19.1(14.1-23.4)vs 1.9(1.9-16.4)ng/l,p=0.02。
- 所有患者接受基于标准化操作流程的治疗,中位7.4天后出院回家。
证据类型、等级与局限
- 证据类型:德国单中心回顾性分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,瑞士与英国PIMS-TS共识声明在真实临床环境中很有价值,便于早期分型和启动特异性治疗,可能改善结局。
- 作者认为,需要额外的随机试验来进一步改善PIMS-TS的管理。
指南或共识出处
- 瑞士与英国PIMS-TS共识声明。
提炼说明
- 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: In the absence of randomised trials for paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV2 (PIMS-TS), optimal management of PIMS-TS-patients remains somewhat uncertain. We aimed to evaluate the practicability of consensus diagnostic/therapeutic pathways in a real-life German hospital setting.
METHODS: All children treated for PIMS-TS (February to November, 2021) at the Childrens' Hospital Kassel were analysed retrospectively. Patients were treated according to local PIMS-TS standardised operating procedure based on the Swiss and UK consensus statements.
RESULTS: Eleven patients treated for PIMS-TS were included in this study (female:male = 2.1:1). According to the categories of the Swiss and UK consensus statements, 36% were uncomplicated hyperinflammation, 36% Kawasaki-like and 27% shock-like disease. Local estimated incidence was 0.92/1000 Covid-19 cases in children aged 4-15 years. Significant inter-group differences in laboratory parameters were found: BNP was highest in shock-like presentation compared to Kawasaki-like and uncomplicated hyperinflammation (median 954 (668-1491) versus 213 (173-934) versus 80 (5-257) ng/l, p = 0.02), whereas troponin was highest in Kawasaki-like, followed by shock-like presentation and uncomplicated hyperinflammation (median 34.7 (27.5-58.4) versus 19.1 (14.1-23.4) versus 1.9 (1.9-16.4) ng/l, p = 0.02). Patients with shock-like presentation needed circulatory resuscitation in the paediatric ICU. All patients received standardised operating procedure-based therapy and were discharged home after a medium of 7.4 days.
CONCLUSION: The Swiss and UK consensus statements on the management of PIMS-TS proved very valuable in a real-life clinical setting, facilitated early categorisation, and initiation of specific therapy, possibly improving the outcome. Additional randomised trials are necessary to further improve the management of PIMS-TS.
参考来源
- Jenke A, Steinmetz M. Paediatric inflammatory multisystem syndrome - temporally associated with SARS-CoV-2 (PIMS-TS) - a German single centre real-life evaluation of the Swiss and UK consensus statements. Cardiol Young. 2022. PMID: 35546290. doi:10.1017/S1047951122001251
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。